Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLIPY1)

• Drug Name: Xmab 5871 Drug Info
• Synonyms: XmAb 5871 (TN)

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 2	[1]
IgG4 related disease	4A43.0	Phase 2	[2]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]
Rheumatoid arthritis	FA20	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DMLIPY1

Molecule-Related Drug Atlas

Drug(s) Targeting Immunoglobulin gamma Fc receptor IIB (FCGR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1206	DMTOMWB	B-cell lymphoma	2A86	Phase 1/2	[6]
MGD010	DMA368V	Autoimmune disease	4A40-4A45	Phase 1	[2]

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[7]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[9]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[10]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[11]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[12]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[13]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[14]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[15]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Modulator	[4]
Immunoglobulin gamma Fc receptor IIB (FCGR2B)	TT5RWKQ	FCG2B_HUMAN	Modulator	[5]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT02867098) XmAb5871 Bioavailability Study
• [4] Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.
• [5] CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
• [6] Clinical pipeline report, company report or official report of BioInvent.
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [13] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [14] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [15] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [16] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL